Another mechanism of action being explored is the targeting of B cell maturation antigen (BCMA), which is an antigen with expression that is primarily restricted to late stages of B cell differentiation (e.g., late memory B cells and plasma cells) and that is also expressed at high levels in malignant multiple myeloma cells [24]. The gene discussed is TNFRSF17; the disease is AL amyloidosis.